The Complete Cellular Energy Peptide Protocol

Your mitochondria are not broken. They are starved, overwhelmed, and running on infrastructure that has not been maintained in years, and the protocol in the video is designed to fix all three of those problems in a specific sequence.

That sequence matters more than any individual compound. So before going deeper on the mechanisms, here is the full chain.

Your cells make energy inside structures called mitochondria, and the actual conversion happens across a membrane inside those structures called the inner mitochondrial membrane. That membrane is made partly of a specialized fat called cardiolipin, which holds the protein complexes of the electron transport chain in the right position to function. When cardiolipin oxidizes and falls apart, those complexes drift, the membrane leaks, and your cells produce more reactive oxygen species, which is the chemical byproduct of inefficient energy conversion, than they produce ATP. As that oxidative damage accumulates over years, cells enter something called senescence, which is a state where the cell stops dividing but refuses to die and instead pumps out inflammatory signals that damage the surrounding tissue. More senescent cells means more inflammation, which means more oxidative stress, which means more membrane damage. That is the loop. The protocol exists to break it.

Now you can go layer by layer into what each tier is actually doing.

The foundation tier is not optional logistics. It is the literal raw material supply chain. Coenzyme Q10 is a molecule that physically carries electrons between the complexes in your electron transport chain, and without it the whole chain slows down regardless of everything else. Magnesium is required to stabilize ATP itself because the molecule your cells use for energy is technically magnesium-ATP, not ATP alone. Zinc is a cofactor in over 300 enzymatic reactions including several involved in mitochondrial function. If any of these are low, you are running the system on a restricted input and adding peptides on top will not compensate for that.

Tier two is NAD+ support, and this requires understanding what NAD+ actually does at a mechanistic level.

NAD+ is something called a coenzyme, which means it is a helper molecule that enzymes need to do their job. Specifically it carries hydrogen ions from one reaction to the next inside the mitochondria, which is how the electron transport chain gets its electrons in the first place. Without enough NAD+, that handoff slows, the chain stalls, and energy output drops.

The reason NAD+ declines with age has to do with an enzyme called NAMPT, which stands for nicotinamide phosphoribosyltransferase, and it is the rate-limiting enzyme in the pathway your body uses to recycle NAD+. NAMPT activity drops significantly as you age, so you produce less NAD+ even if your diet is unchanged.

Here is where the cycling point from the video becomes important from a mechanistic standpoint. If you supplement NAD+ directly or through precursors over a long continuous period, your body can downregulate NAMPT production because it senses adequate NAD+ levels and reduces the signal to make more. So the cycling protocol, 8 to 12 weeks on and 4 to 8 weeks off, is designed to give the system exogenous support while preventing the suppression of your endogenous production pathway. That is not a guess. It is basic receptor and enzyme downregulation biology that applies across most supplementation protocols.

Tier three is where the biology gets more expensive in both cost and mechanism.

As senescent cells accumulate, they do not just sit there quietly. They secrete a mixture of inflammatory cytokines, matrix-degrading enzymes, and growth factors called the senescence-associated secretory phenotype, and that secretion actively damages neighboring healthy cells and impairs mitochondrial function in the surrounding tissue. This means that even if you optimize every input in the earlier tiers, you are fighting against an ongoing inflammatory signal from the senescent cells themselves. Clearing them is not cosmetic. It removes a direct brake on the machinery you are trying to improve.

FOXO4-DRI works by interfering with the survival mechanism senescent cells use to stay alive. Senescent cells upregulate a protein called FOXO4 that suppresses the pro-apoptotic gene p53 and keeps those cells from triggering programmed cell death. FOXO4-DRI is a modified peptide that blocks that interaction, which allows p53 to do its job and drive those cells to apoptosis. In mouse models, the selectivity for senescent cells over healthy cells was 11.73-fold, meaning it was over eleven times more likely to kill a senescent cell than a healthy one. That data is preclinical, and the human equivalent is still unknown.

Tier four is the core of the whole stack and the two compounds in it work on different parts of the same problem.

SS-31, also called elamipretide, is a tetrapeptide that concentrates in the inner mitochondrial membrane and binds directly to cardiolipin, the structural lipid that anchors the electron transport chain complexes. When cardiolipin oxidizes, those complexes physically separate, a process called cristae remodeling, and the efficiency of electron transfer drops sharply. SS-31 stabilizes cardiolipin in a reduced state, keeps the complexes docked, and reduces reactive oxygen species production by roughly 40 to 60 percent in preclinical models. In the TAZ-POWER trial, patients on SS-31 over three years gained a mean of 96 meters on a six-minute walk test and showed a 45 percent improvement in leg strength and cardiac function. That trial involved a specific mitochondrial disease, so extrapolation to healthy aging is limited, but the mechanism is the same infrastructure problem.

MOTS-c comes from a completely different origin. It is something called a mitochondrial-derived peptide, meaning it is encoded in the mitochondrial genome itself, not the nuclear genome, and it is released from the mitochondria and acts like a signaling molecule throughout the body. Its primary mechanism is activation of AMPK, which is an enzyme that functions like a cellular energy sensor, and when AMPK is active it improves insulin sensitivity, shifts cells toward more efficient substrate use, and reduces inflammatory signaling. A 2026 study in Free Radical Biology and Medicine found that MOTS-c also improves intrinsic mitochondrial efficiency, meaning the mitochondria themselves produce more ATP per unit of substrate. SS-31 fixes the infrastructure. MOTS-c optimizes how that infrastructure is used. That is why they can be run together without overlap.

Tier five compounds are corrections for specific dysfunctions rather than universal additions, and understanding why keeps you from adding complexity you do not need.

5-Amino-1MQ targets an enzyme called NNMT, which stands for nicotinamide N-methyltransferase, and NNMT is overexpressed in adipose tissue in people with obesity and metabolic disease. NNMT consumes the methyl groups and NAD+ precursors that would otherwise go toward cellular repair and energy production. In a mouse model, blocking NNMT with 5-amino-1MQ produced a 35 percent reduction in body mass. If you do not have excess adipose tissue with upregulated NNMT, there is nothing to block and no effect to expect.

Most people think of mitochondrial support as something you add to your routine the way you would add a supplement to a shopping cart. The biology says otherwise. The membrane has to be structurally intact before efficiency gains matter. The senescent cell burden has to be reduced before inflammatory suppression allows the machinery to respond. The raw materials have to be present before the signaling compounds have anything to work with. Each layer depends on the one before it, and that dependency is not a sales argument. It is just the order the biology runs in.

---

References

1. Thompson WR et al. TAZ-POWER trial. Genetics in Medicine. 2024;26(7):101133 — SS-31 (elamipretide) +96m on 6MWT, +45% leg strength/cardiac function over 3 years
2. Szeto HH. Mitochondria-targeted cytoprotective peptides. British Journal of Pharmacology. 2014;171:2029-2050 — SS-31 mechanism, cardiolipin binding, 40-60% ROS reduction
3. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015 — MOTS-c AMPK activation, insulin sensitivity
4. Gudiksen A et al. Free Radical Biology and Medicine. 2026;246:682-696 — MOTS-c improves intrinsic mitochondrial efficiency
5. de Keizer et al. Targeted apoptosis of senescent cells. Cell. 2017 — FOXO4-DRI senolytic mechanism, 11.73-fold selectivity
6. Khavinson et al. Epithalon telomerase activation research — limited human + animal data
7. Nkandeu et al. 5-Amino-1MQ mouse study — 35% body mass reduction, NNMT inhibition in adipose tissue

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness